tag:blogger.com,1999:blog-36634196.post5650075361816915992..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: S.R. One 2.0?Chris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36634196.post-74519050261953342342008-05-13T18:04:00.000-05:002008-05-13T18:04:00.000-05:00We all "know the way to San Jose" except biotech a...We all "know the way to San Jose" except biotech and Pharma seem to overlook the possibility.<BR/>VC should encourage growth in this sector because so many people live in San Jose but commute northward for work. There are plenty of buildings standing empty which could be converted for research sites. <BR/>A "green" choice would be San Jose by lessening the 101 or 280 commutes.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-84903069287726392012008-05-07T14:26:00.000-05:002008-05-07T14:26:00.000-05:00I wonder what big pharma will do when it finds no ...I wonder what big pharma will do when it finds no one wants to inlicense its compounds. It's not as though there's a lack of molecules to develop. Finding successful strategies to do so is another matter. Big pharma has well demonstrated an inability to do that. Perhaps the lack of physicians in the management process and an overabundance of MBAs is the problem? Nah, couldn't be. BD is too good to be bothered with needing clinical knowledge or understanding. And big pharma knows how to develop compounds so much better than start-up biotechs, right?! All the more reason to take big pharma's money and/or compounds? How may examples are there of companies built off of big pharma's cast-offs? Can think of many? Neither can I. And that's the point.Anonymousnoreply@blogger.com